Treatment
Figure 2. Initial Assessment and Management of the Patient
With IgAN
IgA-dominant glomerulonephritis (GN)
Idiopathic IgAN
Enroll the patient in a disease registry
Risk stratify the patient using clinical and histologic data.
Quantify progression risk at diagnosis using the
International IgAN Prediction Tool to inform discussions
with patients for shared decision-making.
Commence optimized supportive care:
• Blood pressure (BP) management
• Maximally tolerated dose of ACEi/ARB
• Lifestyle modification
• Address cardiovascular risk
Consider secondary causes:
• IgA vasculitis
• IgAN secondary to:
» Viral (human immunodeficiency virus [HIV],
hepatitis)
» Inflammatory bowel disease
» Autoimmune disease
» Liver cirrhosis
• IgA-dominant infection-related GN
Score the kidney biopsy using the
MEST-C score
